Hemostemix Inc. (HMTXF)
USD 0.07
(2.96%)
USD 0.07
(2.96%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.33 Million CAD | 49.07% |
| 2022 | -4.58 Million CAD | 31.27% |
| 2021 | -6.66 Million CAD | 10.8% |
| 2020 | -7.47 Million CAD | -59.14% |
| 2019 | -4.69 Million CAD | 29.29% |
| 2018 | -6.64 Million CAD | -136.32% |
| 2017 | -2.81 Million CAD | 24.28% |
| 2016 | -3.71 Million CAD | 7.33% |
| 2015 | -4 Million CAD | 7.39% |
| 2014 | -4.32 Million CAD | -185.83% |
| 2013 | -1.51 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -364.09 Thousand CAD | -10.89% |
| 2024 Q1 | -325.74 Thousand CAD | 21.25% |
| 2023 Q4 | -413.64 Thousand CAD | -132.66% |
| 2023 FY | -2.15 Million CAD | 52.92% |
| 2023 Q1 | -1.13 Million CAD | -80.92% |
| 2023 Q2 | -278.7 Thousand CAD | 75.36% |
| 2023 Q3 | -177.78 Thousand CAD | 36.21% |
| 2022 Q4 | -625.31 Thousand CAD | 39.8% |
| 2022 Q2 | -1.58 Million CAD | -18.78% |
| 2022 Q1 | -1.33 Million CAD | 61.75% |
| 2022 FY | -4.58 Million CAD | 31.27% |
| 2022 Q3 | -1.03 Million CAD | 34.45% |
| 2021 Q4 | -3.48 Million CAD | -112.62% |
| 2021 Q2 | -1.4 Million CAD | -116.77% |
| 2021 Q3 | -1.64 Million CAD | -16.9% |
| 2021 FY | -6.66 Million CAD | 10.8% |
| 2021 Q1 | -647.23 Thousand CAD | 83.28% |
| 2020 Q4 | -3.87 Million CAD | -166.23% |
| 2020 FY | -7.47 Million CAD | -59.14% |
| 2020 Q3 | -1.45 Million CAD | 28.99% |
| 2020 Q2 | -2.04 Million CAD | -1614.71% |
| 2020 Q1 | -119.37 Thousand CAD | 78.45% |
| 2019 Q4 | -553.91 Thousand CAD | 57.21% |
| 2019 FY | -4.69 Million CAD | 29.29% |
| 2019 Q1 | -1.5 Million CAD | 23.93% |
| 2019 Q2 | -1.3 Million CAD | 13.38% |
| 2019 Q3 | -1.29 Million CAD | 0.91% |
| 2018 Q2 | -1.79 Million CAD | -37.31% |
| 2018 Q1 | -1.3 Million CAD | -310.75% |
| 2018 FY | -6.64 Million CAD | -136.32% |
| 2018 Q4 | -1.98 Million CAD | -27.72% |
| 2018 Q3 | -1.55 Million CAD | 13.64% |
| 2017 FY | -2.81 Million CAD | 24.28% |
| 2017 Q1 | -537.89 Thousand CAD | 37.27% |
| 2017 Q4 | 621.1 Thousand CAD | 121.6% |
| 2017 Q2 | -475.09 Thousand CAD | 11.68% |
| 2017 Q3 | -2.87 Million CAD | -505.33% |
| 2016 Q4 | -857.48 Thousand CAD | 45.82% |
| 2016 FY | -3.71 Million CAD | 7.33% |
| 2016 Q3 | -1.58 Million CAD | -152.2% |
| 2016 Q2 | -627.59 Thousand CAD | 5.33% |
| 2016 Q1 | -662.94 Thousand CAD | 43.89% |
| 2015 Q1 | -876.34 Thousand CAD | 60.04% |
| 2015 FY | -4 Million CAD | 7.39% |
| 2015 Q4 | -1.18 Million CAD | -19.55% |
| 2015 Q3 | -988.34 Thousand CAD | -3.13% |
| 2015 Q2 | -958.35 Thousand CAD | -9.36% |
| 2014 FY | -4.32 Million CAD | -185.83% |
| 2014 Q4 | -2.19 Million CAD | -163.05% |
| 2014 Q3 | -833.7 Thousand CAD | -2142.1% |
| 2014 Q2 | -37.18 Thousand CAD | -290.63% |
| 2014 Q1 | -9519.00 CAD | 40.39% |
| 2013 Q2 | -35.39 Thousand CAD | 31.73% |
| 2013 FY | -1.51 Million CAD | 0.0% |
| 2013 Q3 | -16.76 Thousand CAD | 52.62% |
| 2013 Q4 | -15.97 Thousand CAD | 4.76% |
| 2013 Q1 | -51.84 Thousand CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -85.774% |
| Skye Bioscience, Inc. | -13.67 Million USD | 82.933% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 102.851% |
| Nascent Biotech, Inc. | -2.22 Million USD | -4.639% |
| Qrons Inc. | -643.67 Thousand USD | -262.498% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -461.597% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 53.745% |
| BioStem Technologies, Inc. | -7.77 Million USD | 70.005% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -239.663% |
| CSL Limited | 3.7 Billion USD | 100.063% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 95.796% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 86.926% |
| Rebus Holdings, Inc. | -664 Thousand USD | -251.403% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -74.724% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -498.947% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 85.297% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.75% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 147.475% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -791.511% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.923% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 18.144% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -51.904% |
| Mesoblast Limited | -84.14 Million USD | 97.227% |
| Marizyme, Inc. | -34.08 Million USD | 93.155% |
| Genus plc | 6.4 Million USD | 136.458% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 123.95% |
| Pharming Group N.V. | -4.87 Million USD | 52.182% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -17.46% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -150.523% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 72.056% |
| ContraFect Corporation | -56.88 Million USD | 95.898% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 48.772% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -66.429% |
| IMV Inc. | -38.67 Million USD | 93.966% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 15.178% |
| MultiCell Technologies, Inc. | -722.81 USD | -322711.942% |
| ONE Bio Corp. | 13.68 Million USD | 117.054% |
| Accustem Sciences Inc. | -3.74 Million USD | 37.719% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 96.045% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -383.026% |
| Q BioMed Inc. | -3.44 Million USD | 32.282% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 165.913% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 11.197% |
| Biomind Labs Inc. | -1 Million USD | -131.112% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 95.755% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 19.575% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 64.902% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -25.153% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -7690.188% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -20.734% |
| GB Sciences, Inc. | -1.42 Million USD | -64.259% |
| Alpha Cognition Inc. | -9.7 Million USD | 75.959% |
| HST Global, Inc. | -140.9 Thousand USD | -1555.927% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -107.423% |
| Halberd Corporation | -75.05 Thousand USD | -3009.017% |
| Enzolytics Inc. | -2.14 Million USD | -8.587% |
| Agentix Corp. | -1.37 Million USD | -70.097% |
| Resverlogix Corp. | -12.74 Million USD | 81.698% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 26.354% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.451% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -123.498% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 20.077% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -47.739% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 31.473% |
| AVAX Technologies, Inc. | 6.69 Million USD | 134.863% |
| Zenith Capital Corp. | -8.94 Million USD | 73.909% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.439% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -13293.703% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 4.969% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1260.459% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -16.389% |
| Kadimastem Ltd | -3.04 Million USD | 23.252% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -137.113% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1185.68% |
| LadRx Corporation | -3.82 Million USD | 38.976% |
| Cell Source, Inc. | -4.32 Million USD | 46.055% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -239.663% |
| NovAccess Global Inc. | -2.46 Million USD | 5.41% |
| Affymax, Inc. | -15.04 Million USD | 84.492% |
| Itoco Inc. | -919.14 Thousand USD | -153.859% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 44.948% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -108.518% |
| Mobile Lads Corp. | -554.55 Thousand USD | -320.759% |
| CytoDyn Inc. | -18.05 Million USD | 87.079% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -9170.23% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -960.223% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -313.179% |
| SYBLEU INC | -149.18 Thousand USD | -1464.095% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -28.464% |
| International Stem Cell Corporation | -663 Thousand USD | -251.933% |
| Bioxytran, Inc. | -3.82 Million USD | 38.921% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4332.593% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -11371.568% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 93.566% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -44.21% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -217.098% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 24.998% |
| Neutra Corp. | -229.48 Thousand USD | -916.758% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 86.696% |
| PureTech Health plc | -146.19 Million USD | 98.404% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 89.143% |
| IXICO plc | -1.43 Million USD | -62.374% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 75.415% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.084% |
| CSL Limited | 3.81 Billion USD | 100.061% |
| Cellectis S.A. | -108.85 Million USD | 97.857% |